PharmaFocus Today – Page 84 – media

No Resistance Found for Baloxavir in China

Roche Pharmaceuticals released a statement saying, “No resistance has been found for Baloxavir in China.” According to authoritative monitoring reports from the World Health Organization (WHO) and the National Centers for Disease Control, Baloxavir currently remains effective against various influenza viruses globally. In China, no strains of the influenza virus exhibiting resistance to Baloxavir have been discovered. The latest data from WHO on the monitoring of antiviral drug-resistant strains show that both Type A and Type B influenza viruses remain sensitive to neuraminidase inhibitors (such as Oseltamivir) and RNA polymerase inhibitors (such as Baloxavir), and treatment remains effective. https://finance.eastmoney.com/a/202501123294373814.html
- Source: drugdu
- 108
- January 14, 2025
36 billion! Stryker swallows up the “peripheral” giant

On January 6, Stryker announced that it would acquire peripheral giant Inari Medical for $80 per share in cash, with a total transaction value of approximately $4.9 billion (approximately RMB 36 billion). The two companies expect to complete the transaction by the end of the first quarter of 2025, but it is subject to the tender of most of Inari’s outstanding shares, regulatory approval and other customary conditions. At the beginning of 2025, the merger and acquisition king Stryker “re-emerged” and threw in a large acquisition case. Behind the first acquisition of the year is the signal that Stryker has officially entered the peripheral vascular market. Why premium acquisitions are favored It is reported that Stryker’s acquisition was a premium acquisition. Before the transaction was announced, Inari Medical’s stock price was about $48, but the actual official acquisition announcement showed that Stryker acquired it at $80 per share in cash. ...
- Source: drugdu
- 140
- January 13, 2025
Domestic bispecific ADCs are authorized to be exported overseas

On January 8, Yingen Bio and Avenzo Therapeutics jointly announced that the two parties have signed an exclusive license agreement. Under the agreement, Avenzo will obtain the exclusive rights to develop, manufacture and commercialize DB-1418/AVZO-1418 worldwide (excluding Greater China). Yingen Bio will receive a down payment of US$50 million and is eligible to receive development, registration and commercialization milestone payments of up to US$1.15 billion. In addition, Yingen Bio is also eligible to receive a share of Avenzo’s sales revenue in its region. It is reported that DB-1418 is an EGFR/HER3 bispecific antibody drug conjugate (ADC) developed by Yingen Bio. It is currently undergoing a new drug clinical trial application (IND) support study and plans to enter the clinical research stage this year. Star Biotech has made another success. According to Yingen Bio’s official information, the company is an innovative biopharmaceutical company in the clinical stage, focusing on the development ...
- Source: drugdu
- 344
- January 13, 2025
Star vaccine may increase risk of rare neurological disease

According to foreign media news, the US FDA requires respiratory syncytial virus (RSV) vaccines produced by Pfizer and GlaxoSmithKline (GSK) to add warnings about the risk of Guillain-Barré syndrome (GBS) on the label. Guillain-Barré syndrome is a rare neurological disease whose cause may be related to infection and immune response. The characteristic symptoms are symmetrical limb weakness, limb numbness, and loss of sensation like wearing gloves and socks, and may cause paralysis. There are currently three RSV vaccines on the market worldwide, namely the recombinant proteins Arexvy (GSK) and Abrysvo (Pfizer), and Moderna’s mRNA vaccine mResvia. The FDA’s regulations involve the first two. The gorgeous opening RSV belongs to the genus Pneumovirus of the family Paramyxoviridae. It is a single-stranded RNA virus that was first isolated from the respiratory tract of chimpanzees in 1956. According to WHO statistics, about 64 million people are infected with RSV each year, and nearly ...
- Source: drugdu
- 174
- January 13, 2025
HPV vaccine changes overnight

Once upon a time, Wantai Bio successfully won the bid for the vaccine procurement project of Jiangsu Government Procurement Network with a price of 86 yuan per dose, which “beat” the price of 2-valent HPV vaccine to less than 100 yuan in one fell swoop, and seized the market with a “discount price”. The 9-valent HPV vaccine is also “not to be outdone”. Merck first expanded the 9-valent HPV vaccine to women aged 9-45 years old, and then signed an exclusive agency agreement with Zhifei Bio with a total amount of over 100 billion yuan, intending to win the Chinese female HPV vaccine market in one fell swoop. On January 8, a new story has begun. Merck announced that several new indications of its quadrivalent human papillomavirus vaccine (brewer’s yeast) have been approved for listing by the National Medical Products Administration and are suitable for vaccination of males aged 9 ...
- Source: drugdu
- 171
- January 13, 2025
One medical device has obtained FDA breakthrough device certification

Recently, the controllable degradation magnesium alloy bone screw developed by Suzhou Innoco Medical Technology Co., Ltd. (hereinafter referred to as Innoco) has been awarded the Breakthrough Device qualification by the US Food and Drug Administration (FDA). It is understood that this is the first biodegradable magnesium alloy orthopedic product in China to pass this certification. Moreover, as the only authoritative certified absorbable orthopedic implant technology enterprise in China, InnoTech has filled this technological gap in the domestic market and broken through the limitations of international similar products in terms of indications. Integrating pioneering technology to solve neck problems Innoco was founded in 2022 and is a high-tech enterprise with innovative technology and independent intellectual property rights. It is committed to the research and industrial transformation of absorbable magnesium alloy materials and advanced orthopedic instruments, and has multiple core technologies such as high-performance magnesium alloy synthesis, controllable degradation composite coating preparation, ...
- Source: drugdu
- 378
- January 10, 2025
The world’s first Simeglutide chewable gummy candy has been launched!

Recently, Eden announced the launch of Simeglutide chewable gummies, the world’s first Simeglutide chewable gummies. This pioneering GLP-1 gummy provides the same active ingredients as compound semaglutide. Eden aims to provide the benefits of GLP-1 drugs such as semaglutide in a convenient form without needle injection, and promote personalized medication for patients. According to the information disclosed on Eden’s official website, the price of Simeglutide chewable gummies includes three options: Eden President Josh Khan said, “At Eden, we are committed to making transformative healthcare services more convenient and accessible. Through this pioneering gummy candy, we eliminate barriers such as needles and discomfort, allowing individuals to explore personalized care plans with healthcare providers to achieve their health goals in a way that suits their lives. This gummy candy is not only a pioneering product in the field, but also meets the growing demand for more convenient alternatives to traditional medicines. Research ...
- Source: drugdu
- 182
- January 10, 2025
Ascentage Pharmaceuticals “advances rapidly”

Ascendance Pharmaceuticals has achieved great success in 2024. The sales of the first commercialized product have been soaring, and the BD transaction with Takeda Pharmaceutical has enabled the company to turn losses into profits for the first time. The pipeline under development is progressing smoothly… Under multiple favorable factors, Ascentage Pharmaceuticals’ share price in 2024 has risen from HK$27 per share at the beginning of the year to HK$45.45 per share, an increase of 68%. If calculated from the low point in April, it has risen by 195%, becoming the “dark horse” among pharmaceutical stocks this year. At the same time, Ascentage Pharmaceuticals has also started the IPO process in the US stock market. Recently, Ascentage Pharmaceuticals’ listing filing for IPO in the US has been confirmed by the China Securities Regulatory Commission, and it plans to issue no more than 33,739,347 common shares and list on the Nasdaq Stock ...
- Source: drugdu
- 131
- January 10, 2025
Now is the best time for influenza vaccination

Recently, China CDC released the latest national sentinel surveillance of acute respiratory infectious diseases. The analysis of the monitoring results shows that, at present, acute respiratory infectious diseases are generally showing a continuous upward trend, and the trends of infection caused by different pathogens are different. Influenza is generally in the seasonal epidemic period, and the positive rate of influenza virus is rising rapidly; among them, the positive rate of influenza virus in outpatient and emergency influenza-like cases nationwide has increased by 6.2% compared with last week. The positive pathogens detected in the outpatient and emergency departments of sentinel hospitals are mainly influenza virus, human metapneumovirus, and rhinovirus, and the positive pathogens detected in hospitalized severe acute respiratory infection cases are mainly influenza virus, Mycoplasma pneumoniae, and human metapneumovirus. In other words, influenza is one of the most important pathogens in both outpatient and emergency cases and inpatient severe cases. ...
- Source: drugdu
- 274
- January 10, 2025
Who will win the world’s first PROTAC drug?

In recent years, the biopharmaceutical market has shown a trend of rapid growth, in which the research and development of innovative drugs has become the focus of attention. As an innovative drug development model, target protein degradation technology has achieved remarkable results in preclinical research. Here, the author combines market trends, research and development progress and other factors to predict the PROTAC drugs that are expected to be approved in 2025, and looks forward to the future development prospects of this technology. Three drugs are making rapid progress Up to now, protein degraders have made significant progress in clinical research. According to incomplete statistics, a total of 36 protein degradation agents have entered the clinical stage around the world, and the total number of protein degradation R&D pipeline projects worldwide has exceeded a thousand. Among the 10 PROTACs that are expected to be approved, the indications are concentrated in cancer, ...
- Source: drugdu
- 224
- January 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.